Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoterMichael Lim, Antonio Omuro, Michael Weller et al.|Neuro-Oncology|2022Cited by 508
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548Michael Weller, Antonio Omuro, Ahmed Idbaïh et al.|Neuro-Oncology|2021Cited by 29
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMASMichael Platten, Wolfgang Wick, Stefan Stevanović et al.|Neuro-Oncology|2018Cited by 26
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Michael Platten, Wolfgang Wick, Daniela Schilling et al.|Journal of Clinical Oncology|2018Cited by 25
VXM01 phase I study in patients with progressive glioblastoma: Final results.Wolfgang Wick, Michael Platten, Antje Wick et al.|Journal of Clinical Oncology|2018Cited by 16